Answers are grounded in this paper and cite their sources.
Esophageal squamous cell carcinoma (ESCC) exhibits substantial inter-patient heterogeneity in response to neoadjuvant immunochemotherapy (NICT), underscoring the need for reliable pre-treatment predictors to guide individualized therapeutic decision-making. In this multicenter study, 102 patients with advanced ESCC receiving NICT were enrolled from two independent institutions. Pre-treatment contrast-enhanced CT images, whole-slide histopathology images, and clinical variables were collected. A habitat-based radiomics strategy was applied to characterize intratumoral heterogeneity, while pathomics features were extracted using a weakly supervised multi-instance learning framework. Optimal single-modality models were identified through systematic feature selection and machine-learning screening. A Transformer-based architecture was subsequently developed to integrate radiomic, pathomic, and clinical signatures into a unified multimodal prediction model (HPTrans). Habitat-based radiomics achieved the best performance among imaging models, with the SVM classifier yielding an AUC of 0.723 (95% CI: 0.580–0.866) in the external validation cohort. For pathomics, a ResNet50-based multi-instance learning model combined with logistic regression demonstrated stable predictive capability (AUC = 0.766, 95% CI: 0.639–0.894). HPTrans outperformed all single-modality approaches, achieving AUC of 0.921 (95% CI: 0.889–0.952) in the training cohort and 0.824 (95% CI: 0.720–0.928) in the external validation cohort. Collectively, HPTrans can accurately predict the efficacy of NICT for patients with advanced ESCC, providing a new and reliable predictive reference for the selection of neoadjuvant treatment regimens for these patients.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: